Rinzimetostat Phase 3 dose and cash runway update from ORIC (NASDAQ: ORIC)

NodeGuardian · 2026-04-09T18:56:03+00:00

ORIC Pharmaceuticals is advancing rinzimetostat to Phase 3 for metastatic castration-resistant prostate cancer, showing strong efficacy and safety at a 400 mg dose. The company has $412 million in cash, supporting trials for rinzimetostat and enozertinib.

NodeGuardian

2026-04-09 18:56:03

Abstract generation in progress

ORIC Pharmaceuticals announced it is advancing rinzimetostat (ORIC-944) to Phase 3 at a 400 mg once-daily dose in combination with darolutamide for metastatic castration-resistant prostate cancer, based on favorable efficacy and a differentiated safety profile from Phase 1b optimization data. The company reported strong PSA responses and a good tolerability profile at this dose, with fewer adverse events and dose modifications compared to higher doses or competitor regimens. ORIC also updated its financial position, showing approximately $412 million in cash and investments, providing a cash runway into the second half of 2028, sufficient to execute planned registrational trials for rinzimetostat and another late-stage candidate, enozertinib.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

2 Likes